Market Analysis on Focal Segmental Glomerulosclerosis Drugs Industry – Insights for Corporate Strategy and R&D
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Focal Segmental Glomerulosclerosis Drugs Market from 2024 to 2025?
There has been a significant expansion in the market size for drugs treating focal segmental glomerulosclerosis in the past few years. The market is projected to increase from $15.77 billion in 2024 to $17.08 billion in 2025, registering a compound annual growth rate (CAGR) of 8.3%. Factors such as rising prevalence of the disease, increasing demand for novel treatment options, heightened interest from the pharmaceutical industry, and augmenting governmental aid have contributed to growth during the historical period.
What Is the Projected Market Size of the Focal Segmental Glomerulosclerosis Drugs Market?
The market size for drugs related to focal segmental glomerulosclerosis is anticipated to experience robust growth in the upcoming years. The prediction is that it will escalate to $24.87 billion by 2029, growing at a compound annual growth rate (CAGR) of 9.8%. The growth projected over the forecast period may be driven by factors such as research and development spending, increased healthcare costs, heightened awareness and diagnosis, an older population, and government-led initiatives and financial support. Major trends for the forecast period encompass advances in technology for drug discovery and development, an enlarging clinical trial pipeline, better insurance coverage for focal segmental glomerulosclerosis drug treatments, and the expansion of corporate research facilities.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12866&type=smp
Who are the Major Competitors in the Focal Segmental Glomerulosclerosis Drugs Market Outlook?
Major companies operating in the focal segmental glomerulosclerosis drugs market are Pfizer Inc., Johnson and Johnson Ltd., F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca PLC, Fresenius Kabi Ltd., GSK PLC, Medtronic Plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd., Mylan N.V., B. Braun Melsungen AG, Hikma Pharmaceuticals PLC, Alexion Pharmaceuticals, Wockhardt, Travere Therapeutics, Aurinia Pharmaceuticals Inc., Omeros Corporation, Dimerix Ltd., Goldfinch Bio.
What Is Fueling Growth in the Focal Segmental Glomerulosclerosis Drugs Market?
The escalating incidence rates of kidney infections are anticipated to boost the evolution of the focal segmental glomerulosclerosis (FSGS) drugs market. Kidney infection, or pyelonephritis, is a severe urinary tract infection (UTI) affecting one or both kidneys. The administration of FSGS drugs is beneficial in treating kidney ailments, enhancing kidney function by minimizing proteinuria, decelerating kidney damage progression, and providing improved quality of life for kidney disease patients. For instance, data from the Centers for Disease Control and Prevention, a Health and Human Services department in the US, showed that kidney disease had afflicted around 15% or 37 million Americans in July 2022. Among individuals aged 45–64, prevalence is at 12%, and among people aged 18-44, the prevalence was 6% in 2021. Thus, escalated incidences of kidney infections bolster the FSGS market. The focal segmental glomerulosclerosis drugs market’s upward trajectory can also be attributed to increasing healthcare expenditure. Such expenditure is the aggregate sum spent on health services, related goods, and activities within a healthcare system or economy during a specific period. Mounting healthcare costs are advantageous for creating and making FSGS drugs more accessible. They augment funding for research and clinical trials, thereby enhancing drug production. The Canadian Institute for Health Information reported in November 2023 that Canada’s total health spending for 2023 is projected at $344 billion, averaging $8,740 per person. This signifies a 2.8% increase compared to the previous year of 2022, witnessing only a 1.5% rise in health spending, underscoring a significant resurgence in healthcare investment. Therefore, mounting healthcare expenses propel the growth of the FSGS drugs market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=12866&type=smp
Which Focal Segmental Glomerulosclerosis Drugs Market Segments Are Growing the Fastest?
The focal segmental glomerulosclerosis drugs market covered in this report is segmented –
1) By Type: Losmapimod, SHP-627, Sparsentan, TM-5484, Other Types
2) By Treatment: Corticosteroids, Immunosuppressive Drugs, Angiotensin Converting Enzymes (ACE) Inhibitors, A.R. Blockers, Diuretics, Other Treatments
3) By Route of Administration: Oral, Parenteral
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Which Industry Trends Are Shaping the Future of the Focal Segmental Glomerulosclerosis Drugs Market?
Significant players in the focal segmental glomerulosclerosis (FSGS) market are progressively directing their efforts towards product evolution and novelty to offer dependable products to their clients and consolidate their market standing. For example, in February 2023, Travere Therapeutics, an American biopharmaceutical firm, debuted FILSPARI, designed for focal segmental glomerulosclerosis (FSGS). This product received approval from the US-based federal agency, the Food and Drug Administration (FDA). FILSPARI, an oral medication for managing IgA nephropathy (IgAN), is a pioneering non-immunosuppressive solution aimed at reducing proteinuria in cases of IgAN, a rare kidney condition. Further, FILSPARI has secured orphan drug status in both the United States and Europe for the treatment of IgAN and focal segmental glomerulosclerosis (FSGS).
Access The Full Report Here:
Which Countries Are Leading the Focal Segmental Glomerulosclerosis Drugs Market?
North America was the largest region in the focal segmental glomerulosclerosis drugs market in 2024. The regions covered in the focal segmental glomerulosclerosis (FSGS) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12866
This Report Delivers Insight On:
1. How big is the focal segmental glomerulosclerosis drugs market, and how is it changing globally?
2. Who are the major companies in the focal segmental glomerulosclerosis drugs market, and how are they performing?
3. What are the key opportunities and risks in the focal segmental glomerulosclerosis drugs market right now?
4. Which products or customer segments are growing the most in the focal segmental glomerulosclerosis drugs market?
5. What factors are helping or slowing down the growth of the focal segmental glomerulosclerosis drugs market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
